The study on the development of the composition of chewable lozenges with probiotic properties. 1. Substantiation of the active substance

Abstract

In recent times, a new understanding of the concept of probiotics has emerged – the use of their metabolites instead of living cells of microorganisms. They can both inhibit the development of pathogenic bacteria and effectively stimulate the reproduction of indigenous microflora. It is possible that metabiotics will be more effective than traditional live probiotics. Taking into account the prospects of new-generation probiotic drugs and the rapid growth of interest of
pharmaceutical market entities in such a new dosage form as lozenges, we have proposed to create chewable lozenges containing Lactobacillus exometabolites, which pharmacological action is aimed at preventing and treating an imbalance
of the oral cavity microflora.
Aim. To theoretically and experimentally substantiate the choice of the exometabolite complex of lactobacilli as the active substance of a medicinal product with probiotic properties in the form of chewable lozenges.
Materials and methods. The exometabolite complex of the Lactobacillus plantarum UCM-2693 strain was used as the study object. Acidity, the lactic acid content, the optical density of a microbial suspension, as well as the quantitative count of lactobacilli were determined in accordance with the generally accepted methods specified in the State
Pharmacopoeia of Ukraine (SPhU).
Results and discussion. The bacteriotropic effect of the exometabolite complex of L. plantarum UCM-2693 was detected on lactobacilli of the probiotic drug “Lactobacterin-Biopharma” when cultured on a medium with exometabolites compared to the control sample. This technique has a stimulating effect on the acid formation, proliferation of
probiotic microorganisms, changes the characteristics of their growth phases, namely reduces the lag phase, accelerates the exponential phase, which can accelerate the onset of the therapeutic effect, and is the proof of the feasibility
of using this active substance in the composition of chewable lozenges with probiotic properties.
Conclusions. The choice of the exometabolite complex of lactobacilli as the active substance of a new drug from the group of metabiotics in the form of chewable lozenges has been substantiated. The exometabolite complex of lactobacilli has been obtained, and its bacteriotropic effect has been studied.